VRX : Analysis & Opinions

  • Showing 1-100 of 105 items
  • 1
  • 2
  • >>
  1. Short Sellers Now Fleeing Valeant Stock

    January 17, 2017
    The extent to which Valeant's asset sales can bring its share price back from the dead is now being hotly debated.
  2. Bill Ackman Eases Into the New Year

    January 17, 2017
    The Pershing Square founder is likely relieved to have started 2017 a bit more quietly.
  3. Valeant Soars 14% on $2.12B Worth of Asset Sales

    January 11, 2017
    Valeant obtained some much needed debt relief by offloading multiple assets.
  4. Valeant Stock Gains on Possible Salix Interest

    January 10, 2017
    Could the failed Salix sale, which sunk Valeant shares in November, be back on the table?
  5. Why Valeant Stock Rose 5.5% Last Week

    January 9, 2017
    The company is seeing positive signs so far in 2017, as its share performance beat the 1.7% rise in the S&P 500 Index.
  6. The Biggest Hedge Fund Failures of 2016

    January 6, 2017
    In a bad year for hedge funds, these firms stood out for their failures.
  7. Health Care Stocks With Short-term Upside (AGN)

    January 4, 2017
    While these trades should be considered risky, recent strength indicates a potential short-term turnaround in these pharmaceutical ...
  8. Will Valeant Stock Remain Toxic in 2017?

    January 3, 2017
    After losing some 86% of its value last year, Valeant doesn't have to be extraordinary in 2017 to have a bounce-back year.
  9. Valeant's Meltdown in 2016: A Year In Review

    December 28, 2016
    The embattled drug company, whose year was marred by lawsuits and controversy, has time to change its course
  10. The Worst Performing Stocks on U.S. Exchanges in 2016

    December 23, 2016
    Valeant plummeted by more than 80%. Here's a list of the worst performing stocks listed on the NYSE and the NASDAQ.
  11. Ackman's Pershing Sq. Dumps 3.4M Valeant Shares at a Loss

    December 14, 2016
    This is not a test. This time he's possibly dumping the shares for real.
  12. Valeant Stock Falls as Three Top Executives Quit

    December 13, 2016
    With three high-level executives leaving, Valeant's already unstable business will likely be on shakier ground.
  13. Can Donald Trump Make Valeant Stock Great Again? (VRX, XLV)

    December 5, 2016
    Shares of Valeant have been under heavy selling pressure over the past month, plunging as much as 27% from around $22 to ...
  14. Valeant Stock Plunges 11% on Failed Salix Sale

    December 1, 2016
    Reports that the Salix deal could be off the table have to be a disappointment for investors, who have suffered from nothing ...
  15. Valeant Stock Could Fall 35%: Analyst (VRX)

    November 25, 2016
    Shares of Valeant Pharmaceuticals could fall 35% from current levels, based on a recent note by analysts at Mizuho Securities.
  16. Valeant Stock Attracting More Short Sellers (VRX)

    November 21, 2016
    With $31 billion in debt crippling the company, combined with limited routes to grow revenue, short sellers see a solid opportunity ...
  17. Valeant Suffers From Too Much Legal Risk: Wells Fargo (VRX)

    November 18, 2016
    Valeant is still the subject of almost a dozen different government probes, in addition to numerous shareholder lawsuits, ...
  18. Ex-Valeant Execs Tied to Philidor Charged in Fraud

    November 17, 2016
    Shares of Valeant are under heavy selling pressure Thursday on reports that former execs with ties to mail-order company ...
  19. Billionaire James Chanos: Valeant is Worse than Enron

    November 17, 2016
    Chanos, head of Kynikos Associates, says a bad bet on Valeant cost the industry $40 billion.
  20. Why Valeant Stock Declined 6% Last Week (VRX)

    November 14, 2016
    Depending on who you ask, Valeant is on the verge of a painful death, or the embattled Canadian drug company is just misunderstood. ...
  21. Valeant Stock Falls 28% on Earnings, Historic Lows

    November 8, 2016
    With the shares now down 85% year to date, driven but alleged accounting problems, the new Valeant can't come fast enough.
  22. Two Villains At Bat On Election Day (SEAS, VRX)

    November 7, 2016
    Market villains SeaWorld and Valeant Pharmaceuticals report earnings on the same day that Americans head to the polls.
  23. Valeant Sued: Female Libido Drug Was a Dud (VRX)

    November 6, 2016
    Valeant was sued for allegedly failing to properly market a "blockbuster" female libido pill whose sales fizzled as a result.
  24. Valeant May Sell Stomach Drug Ops for $10B (VRX)

    November 2, 2016
    Cash-strapped Valeant is in talks to sell its stomach drug business for $10 billion.
  25. Pharma Stocks Prone to Decline From Democratic Win (MYL, ARIA)

    October 17, 2016
    Amid the political bashing of price raises by drug manufacturers, here are the stocks most prone to declines.
  26. How Valeant’s Scandal Has Impacted Its Stock Price (VRX)

    September 30, 2016
    Since its peak price on August 5, 2015, Valeant’s shares have lost 86% of their value.
  27. Revisiting Three Market Villains (CMG, VRX)

    September 27, 2016
    Mylan, Chipotle, and Valeant Pharmaceuticals CEOs have learned that traders have the final word when executives fail to address ...
  28. Wealth Preservation: "All I Know Is That I Know Nothing"

    September 25, 2016
    Investors can derive great value from humility. By keeping the adage "all I know is that I know nothing" in mind, they can ...
  29. Ackman's Pershing Square Bets on Chipotle (CMG, VRX)

    September 7, 2016
    The activist hedge fund mogul's bullish stance on Chipotle has sent shares up 4.8% at open Wednesday
  30. Is Mylan The Next Valeant Trade? (MYL, VRX)

    September 2, 2016
    Mylan is caught in a political firestorm after EpiPen price increases while short sellers drool over a possible Valeant Pharmaceuticals ...
  31. Bill Ackman's Cry: "Worst Period Of Performance" (HLN, VRX)

    August 31, 2016
    Pershing Square Holding’s year-to-date performance is -15.5%.
  32. Valeant International Sued For Alleged Racketeering (VRX)

    August 29, 2016
    The class action suit claims that Valeant overcharged the buyers for prescription drugs by hiding its relationship with Philidor ...
  33. Pershing Square Cuts Positions to Fight Losses (VRX, ZTS)

    August 21, 2016
    Bill Ackman's fund, attempting to deal with significant losses, cuts positions in major stakes.
  34. T. Rowe Price Sues Valeant Pharmaceuticals For Fraud (TROW, VRX)

    August 19, 2016
    T. Rowe Price has launched a lawsuit against Valeant Pharmaceuticals, claiming it committed fraud that cost it and other ...
  35. Valeant Shares Plunge Amid Criminal Probe (VRX)

    August 10, 2016
    Federal prosecutors have launched a criminal investigation to determine whether Valeant defrauded insurers.
  36. 8 Stocks for Active Traders (VRX,FCX,F,BAC,SIRI)

    August 10, 2016
    These eight stocks have the potential to deliver significant returns in a short period of time.
  37. Valeant Q2 Earnings: What to Expect

    August 8, 2016
    Wall Street expects the embattled drug company to deliver year-over-year declines in both earnings and revenue.
  38. Ackman's Bad Bets Costs $600 Million in Redemptions

    July 24, 2016
    If Ackman's losing streak continues, his investors may begin to factor in their own poor decisions to stick with him.
  39. Bill Ackman's Assault on Herbalife Fizzles

    July 19, 2016
    The FTC's settlement and the subsequent rise in Herbalife stock is a major blow to Ackman, whose hedge fund is on a losing ...
  40. Sequoia Fund Exits Entire Valeant Stake

    July 14, 2016
    With Valeant stock rebounding almost 18% just in the past five days and rising 25% from its low through Tuesday's close, ...
  41. Valeant Surges 16% Since Walgreens Is "Satisfied"

    July 6, 2016
    The talks between the two companies have been positive. Short sellers were scrambling on Wednesday to cover their bets.
  42. Ackman's Pershing Square Down 20%

    July 6, 2016
    The firm also let go of 10% of its back-office staff.
  43. Brexit Fallout: Outlooks Diverge on Valeant (VRX)

    July 5, 2016
    Patient investors can gain 22%, according to BMO analysts, but other firms see major global risk ahead related to Brexit ...
  44. Ackman vs. Madoff: Who's Hurting Hedge Funds More?

    July 1, 2016
    Compare the plights of former and current money managers Bernie Madoff and Bill Ackman and how the actions of both men have ...
  45. More Bad News for Ackman? (PSHZF)

    July 1, 2016
    Discover reasons why Bill Ackman's Pershing Square may suffer again in 2016 due to Saudi Arabia's move to ban derivatives ...
  46. Is Einhorn Investing in the Next Valeant Stock? (VRX)

    June 29, 2016
    Learn why famed hedge fund manager David Einhorn initiated a long position in Mylan despite regulatory concerns about the ...
  47. Brexit Could Impact Valeant's Asset Sales (VRX)

    June 28, 2016
    Britain's decision Friday to leave the European Union could negatively impact the company's divestment plans.
  48. Bill Ackman on Concentrated Portfolios, Lessons From Valeant ...

    June 27, 2016
    Explore the lessons of concentrated portfolios, including how Bill Ackman's strategy change at Pershing Square mirrors one ...
  49. Valeant Falls As Barclays Sees 'No Short-Term Fix' (VRX, WBA)

    June 16, 2016
    Beyond poor deals, Valeant's acquisition spree, which has ballooned its debt level to over $31 billion, remains a drag on ...
  50. Valeant's CEO Joseph Papa Buys 202,000 Shares (VRX)

    June 14, 2016
    Joseph Papa affirmed Monday that he believes in his own turnaround strategy for Valeant.
  51. Index Funds: The Case Against Bill Ackman (STT, BLK)

    June 11, 2016
    Explore the reasoning behind Bill Ackman's concern of an impending index fund bubble, and why his argument sounds like an ...
  52. Valeant: Why Drug Price Cuts Not Seen Yet (VRX, WBA)

    June 10, 2016
    Learn the details of the Valeant scandal, look into the Citron accusations and Valeant's defense, and find out where Valeant ...
  53. Valeant's Positive Aspects Overlooked: Analyst (VRX)

    June 9, 2016
    Guggenheim's comments come on the heels of Valeant suffering massive declines in two of the company's key categories, dermatology ...
  54. Valeant Stock Falls on Wider Loss, Guidance Miss (VRX)

    June 7, 2016
    Combined with weak guidance for the second quarter, the optimism recently created from the arrival of its new CEO seems to ...
  55. Bill Ackman's Pershing Square Down 18.6% as of May

    June 6, 2016
    Betting on a Pershing Square recovery is a bet not only Bill Ackman, it's also a wager that Valeant can eventually get its ...
  56. Valeant Stock Rises Ahead of Q1 Earnings (VRX)

    June 6, 2016
    Wall Street expects the beleaguered drug company to deliver a year-over-year decline in earnings, while revenue is expected ...
  57. Bill Ackman Is Against Mutual Funds: Should Investors Listen? ...

    June 5, 2016
    Learn about Bill Ackman's view of index funds and how passive management ignores stock valuation, leading U.S. equities to ...
  58. 3 Lessons From Hedge Funds' Favorite Stocks (HTZ, VRX, SUNEQ)

    June 4, 2016
    Learn about the increasing influence of hedge fund managers on investors and how the stock selection of the pros should always ...
  59. The Legal Way to Get a Bigger Bonus Than You Earned

    June 1, 2016
    Non-GAAP metrics already have some investors riled up. But what happens when companies determine executive pay using “earnings ...
  60. Biotech Stocks: Are They Back?

    June 1, 2016
    The bearish trends over the past year have started to reverse themselves which has benefted the biotech industry
  61. Valeant's Outgoing CEO Gets $9M Severance and More (VRX)

    June 1, 2016
    J. Michael Pearson, CEO of Valeant until May 2, will receive a $9 million severance payment. Valeant's stock has fallen 9 ...
  62. 4 Lessons Valeant Can Teach Investors (VRX)

    June 1, 2016
    Learn about the storied tumble of Valeant Pharmaceuticals Inc. and the subsequent effect on institutional and individual ...
  63. Valeant Stock Surges After Rejecting Takeover Bids (VRX)

    May 31, 2016
    The fact that there are interested buyers in the beleaguered drug company suggests Valeant still has some appreciable value.
  64. Biotech ETFs: Why Valeant May Cause Contagion Risk (VRX)

    May 26, 2016
    Learn about Valeant Pharmaceutical's scandal that caused its stock to plunge over 90%, and why biotech ETF investors should ...
  65. SEC Investigating Valeant's Use of Non-GAAP Metrics (VRX)

    May 25, 2016
    The SEC is not amused with Valeant's use of non-GAAP financial metrics.
  66. Valeant Gets Default Notice, Senior VP Resigns (VRX)

    May 23, 2016
    The filing delays are related to federal regulators investigating Valeant's accounting practices linked to its dealings with ...
  67. Valeant Falls After Questionable Bonus Payments (VRX)

    May 20, 2016
    Wells Fargo senior analyst David Maris has taken issue with what appears to be a brash statement by the embattled drug company.
  68. Valeant Stock Rises on Possible Asset Sale (VRX)

    May 18, 2016
    Whether these maneuvers will have any material effect on the company is not clear.
  69. Is the Hedge Fund Industry Peaking?

    May 14, 2016
    Learn if the hedge fund industry has crested, and explore the characteristics of the fund community that may have implications ...
  70. Valeant Stock Declines on Hospitals' Price Claims (VRX)

    May 13, 2016
    Shares of Valeant declined almost 11% Thursday after several hospitals complained they had not received promised drug discounts.
  71. Valeant Stock Plummets on Jim Chanos' Short Bet (VRX)

    May 9, 2016
    Famed short seller Jim Chanos last week fanned the flames of doubt about Valeant's future.
  72. 3 Catalysts That Will Drive AERI Higher in 2016 (AERI, VRX)

    May 8, 2016
    Read about the key drivers of Aerie Pharmaceuticals' stock price, which has been volatile since the company's IPO.
  73. 6 Reasons to Watch Kythera Biopharm Inc. (AGN, PFE)

    May 1, 2016
    Discover why the Russell 2000 and other investment indexes believe California-based Kythera Biopharmaceuticals Inc. is a ...
  74. Valeant Files Late Annual Report, Restates Results (VRX)

    April 29, 2016
    Valeant Pharmaceuticals filed its overdue 10-K form with the SEC Friday, restating revenues and profits for 2014 and much ...
  75. Valeant Announces New CEO (VRX)

    April 25, 2016
    The embattled Canadian drug maker announced that Joseph Papa, former CEO of Perrigo Co., would be its CEO this morning.
  76. (VRX) Who are Valeant's Main Competitors?

    April 23, 2016
    Learn which companies Valeant is likely watching closely, since it is known for acquiring companies for their products rather ...
  77. Top 3 Companies Owned by Valeant (VRX)

    April 23, 2016
    Learn more about Valeant Pharmaceuticals International Inc. and three of the top companies that Valeant owns or operates ...
  78. Valeant News: Michael Pearson's Return, Sort of

    April 18, 2016
    Explore the circumstances surrounding Michael Pearson’s leave of absence from Valeant, as well as the details of his short-lived ...
  79. Valeant vs. Abbott Labs: Which Is Better for My Portfolio? (VRX, ...

    April 16, 2016
    Explore the differences between Abbott Laboratories and Valeant Pharmaceuticals, as well as which stock is the best addition ...
  80. Deconstructing Two Notorious Story Stocks (VRX, CMG)

    April 8, 2016
    Valeant and Chipotle are once-respected brands that have been undermined by scandals, but traders aren't complaining.
  81. Bill Ackman's Greatest Hits and Misses

    March 22, 2016
    With the recent Valeant fiasco, we take a look back at the best and worst of the gray haired hedge fund manager.
  82. Valeant CEO Steps Down (VRX)

    March 21, 2016
    The markets started on a lower note this morning as equity and commodity prices took a breather from recent rallies.
  83. FedEx Soars, Ackman Sells Mondelez (FDX, MDLZ)

    March 17, 2016
    Shares for FedEx (FDX) rose to their highest level in nearly three months after the logistics giant reported results that ...
  84. How Low Will Valeant Go? (VRX)

    March 16, 2016
    A week after its stock price surged, Valeant Pharmaceuticals International Inc. is down in the dumps once again.
  85. Markets Cautious Ahead of Tomorrow's Fed Meeting (VRX, DSW)

    March 15, 2016
    Declining oil prices and the Federal Reserve meeting are on the market's mind this morning.
  86. 4 Reasons Behind Bill Ackman's Purchase of Zoetis Stock (ZTS, ...

    March 15, 2016
    Find out the reasons behind activist hedge fund manager Bill Ackman's 10% stake in Zoetis, Inc., and learn his plans for ...
  87. Why Valeant Pharmaceuticals Surged 13% Last Week (VRX)

    March 14, 2016
    While VRX shares may look attractive today, take Person's "There is no other big shoe to drop" remark at your own peril.
  88. Bill Ackman's Success Story: Net Worth, Education & Top Quotes ...

    March 7, 2016
    Read about William Ackman, Pershing Square Capital Management's confident and brash portfolio manager and famous activist ...
  89. Top 5 Positions in John Paulson's Portfolio (AGN, VRX)

    February 29, 2016
    Find out which stocks are holding the top five positions in investment guru John Paulson's hedge fund portfolio and which ...
  90. 3 Volatile U.S. Industries to Exploit in 2016 (VRX, IBB)

    February 13, 2016
    Read about volatile sectors in the stock market that may provide opportunities for investors in 2016, including energy, mining ...
  91. Bill Ackman's 2 Best Investments (GGP, CP)

    February 10, 2016
    Learn about the two best investments Ackman ever made. Ackman has demonstrated a consistent track record of success in all ...
  92. Under Pressure: Eyeing Pershing Square's Holdings

    February 2, 2016
    A look at Pershing Square's recent performance, portfolio and future outlook. Should investors follow the money?
  93. Allergan: An Activist Investment Analysis (AGN,VRX)

    January 28, 2016
    Read about the activist investor campaign against Allergan by Bill Ackman. See how Ackman partnered with another drug company ...
  94. The Top 3 Biotechnology Stocks for 2016 (AMGN, VRX)

    December 30, 2015
    Find out more about the top three biotechnology stocks to consider in 2016, and learn about their characteristics and why ...
  95. Valeant Shares up on Walgreens Deal

    December 15, 2015
    Shares of Valeant Pharmaceuticals rose by 15% after it announced a new drug pricing and distribution agreement with Walgreens ...
  96. Congressman Questions VW's "Road of Deceit" (KING, ATV)

    November 3, 2015
    The U.S. EPA​ widened its probe against Volkswagen saying the car maker used the defeat device on other V6 engines to comply ...
  97. 3 Answers For Valeant Investors (VRX)

    October 26, 2015
    Valeant Pharmaceutical Inc., held an investor call to clarify its relationship with specialty pharmaceutical firms. Here ...
  98. Will Valeant's Mea Culpa Save Its Stock?

    October 26, 2015
    This morning, Canadian pharmaceutical maker Valeant Pharmaceuticals International Inc. (VRX) announced a public conference ...
  99. More Volatility Ahead

    September 29, 2015
    Yesterday started the week with a dose of fear as the VIX shot up by almost 17 percent. The index has been consistently trending ...
  100. Valeant Pharmaceuticals acquires Sprout Pharmaceuticals (VRX)

    August 21, 2015
    On August 20, 2015, Valeant Pharmaceuticals (VRX) announced that they entered into definitive agreement to acquire Sprout ...
  • Showing 1-100 of 105 items
  • 1
  • 2
  • >>